Ocular Therapeutix Inc
Change company Symbol lookup
Select an option...
OCUL Ocular Therapeutix Inc
FCO Aberdeen Global Income Fund Inc.
DTEC ALPS Disruptive Technologies ETF
$RUIRETAILT Russell 1000 RGS Retail Total Return
BAC Bank of America Corp
MA Mastercard Inc
AAPL Apple Inc
AA Alcoa Corp
AMD Advanced Micro Devices Inc
PFE Pfizer Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Closing Price
$19.91
Day's Change
-0.17 (-0.85%)
Bid
--
Ask
--
B/A Size
--
Day's High
20.56
Day's Low
19.07
Volume
(Heavy Day)
Volume:
941,619

10-day average volume:
774,244
941,619

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase III clinical development for glaucoma and ocular hypertension. Its earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor, and, in collaboration with Regeneron an extended release protein-based anti-vascular endothelial growth factor trap.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
122.83x
Price/Book (MRQ)
--
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

December 2020
Current Month
5.8M
Previous Month
5.0M
Percent of Float
8.12%
Days to Cover
4.4503 Days

Share Information

OCUL is in a share class of common stock
Float
71.8M
Shares Outstanding
75.3M
Institutions Holding Shares
143
54.29%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Charles M. WardenChmn.
  • Antony Charles MattessichPres.
  • Donald D. NotmanCFO
  • Michael H. GoldsteinCorp.Exec.
  • Patricia KitchenCOO

Address

Insider Trading

During the most recent quarter, 440 shares were bought, and 25K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.